Abrogation of tumor vasculature using gene therapy

Cancer and Metastasis Reviews

Volumn 19, Issue 1-2, 2000, Pages 45-49

  Nesbit, M ^a  

^a Department of Antiangiogenesis ^*  (United States)

Author keywords

Adenovirus; Angiogenesis; Gene therapy; Tumor

Indexed keywords

ANGIOGENESIS INHIBITOR; GREEN FLUORESCENT PROTEIN;

ANIMAL CELL; CANCER GENETICS; CELL MATURATION; ENDOTHELIUM CELL; EXTRAVASATION; GENE TARGETING; GENE THERAPY; GROWTH INHIBITION; HYPOXIA; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; REPORTER GENE; REVIEW; SOLID TUMOR; TUMOR GROWTH; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; COLLAGEN; ENDOSTATINS; GENE THERAPY; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDE FRAGMENTS;

EID: 0034531945     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1026588028780     Document Type: Review

References (58)

1. What is the evidence that tumors are angiogenesis dependent?
2. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF
3. Hypoxia-mediated apoptosis from angiogenesis inhibition underlies tumor control by recombinant interleukin 12
4. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
5. Multistep nature of metastatic inefficiency: Dormancy of solitary cells after successful extravasation and limited survival of early micrometastases
6. Regulation of uveal melanoma interconverted phenotype by hepatocyte growth factor/scatter factor (HGF/SF)
7. An address system in the vasculature of normal tissues and tumors
8. Targeting of adenovirus penton base to new receptors through replacement of its RGD motif with other receptor-specific peptide motifs
9. Efficient adenoviral gene transfer to kidney cortical vasculature utilizing a fiber modified vector
10. Inhibition of tumor growth, vascularization, and collagenolysis in the rabbit cornea by medroxyprogesterone
11. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth
12. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma
13. Angiostatin induces and sustains dormancy of human primary tumors in mice
14. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance
15. Angiostatin gene transfer: Inhibition of tumor growth in vivo by blockage of endothelial cell proliferation associated with a mitosis arrest
16. Anti-angiogenic agents
17. Kringle domains of human angiostatin. Characterization of the antiproliferative activity on endothelial cells
18. Kringle 5 of plasminogen is a novel inhibitor of endothelial cell growth
19. Characterization of kringle domains of angiostatin as antagonists of endothelial cell migration, an important process in angiogenesis
20. Prothrombin kringle-2 domain has a growth inhibitory activity against basic fibroblast growth factor-stimulated capillary endothelial cells
21. Nk4, a new HGF/SF variant, is an antagonist to the influence of HGF/SF on the motility and invasion of colon cancer cells
22. Anti-angiogenic activity of the cleaved conformation of the serpin antithrombin
23. Adenovirus-mediated delivery of a uPA/uPAR antagonist suppresses angiogenesis-dependent tumor growth and dissemination in mice
24. Canstatin, a novel matrix-derived inhibitor of angiogenesis and tumor growth
25. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth
26. Angiogenesis and tumor metastasis
27. Blood vessel maturation: Vascular development comes of age
28. Endothelial cells modulate the proliferation of mural cell precursors via platelet-derived growth factor-BB and heterotypic cell contact
29. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal
30. Adeno-associated virus-mediated delivery of antiangiogenic factors as an antitumor strategy
31. Development of lentiviral vectors for gene therapy for human diseases
32. The molecular pathogenesis of Semliki Forest virus: A model virus made useful?
33. Progress in cancer gene therapy
34. Long-term, high level in vivo gene expression after electric pulse-mediated gene transfer into skeletal muscle
35. High-efficiency gene transfer into skeletal muscle mediated by electric pulses
36. Systemic inhibition of tumor growth and tumor metastases by intramuscular administration of the endostatin gene
37. Liposomes complexed to plasmids encoding angiostatin and endostatin inhibit breast cancer in nude mice
38. Adenovirus-mediated gene transfer of endostatin in vivo results in high level of transgene expression and inhibition of tumor growth and metastases
39. Anti-angiogenic gene therapy of cancer utilizing a recombinant adenovirus to elevate systemic endostatin levels in mice
40. The tumor-suppressing activity of angiostatin protein resides within kringles 1 to 3
41. Anti-angiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2
42. Endothelial-perivascular cell signaling in vascular development: Lessons from knockout mice
43. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis
44. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis
45. Induction of the angiogenic phenotype by Hox D3
46. Systemic delivery of anti-angiogenic adenovirus AdmATF induces liver resistance to metastasis and prolongs survival of mice
47. Viral vector-mediated transduction of a modified platelet factor 4 cDNA inhibits angiogenesis and tumor growth
48. Viral vector-targeted anti-angiogenic gene therapy utilizing an angiostatin complementary DNA
49. Platelet factor-4 inhibits the mitogenic activity of VEGF121 and VEGF165 using several concurrent mechanisms
50. Platelet factor 4 modulates fibroblast growth factor 2 (FGF-2) activity and inhibits FGF-2 dimerization
51. Transfer of the murine interleukin-12 gene in vivo by a Semliki Forest virus vector induces B16 tumor regression through inhibition of tumor blood vessel formation monitored by Doppler ultrasonography
52. Tumor cell responses to IFNgamma affect tumorigenicity and response to IL-12 therapy and antiangiogenesis
53. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity
54. Anti-angiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer
55. Combined effects of radiotherapy and angiostatin gene therapy in glioma tumor model
56. Replication-selective adenoviruses as oncolytic agents
57. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice
58. Tumor development under angiogenic signaling: A dynamical theory of tumor growth, treatment response, and postvascular dormancy